Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A vaccine component consisting of Neisseria meningitidis serogroup Y capsular polysaccharide that has been chemically conjugated to diphtheria toxoid protein. This conjugation enhances immunogenicity by converting the T-cell independent polysaccharide antigen into a T-cell dependent antigen, resulting in improved immune response, particularly in infants and young children. This antigen is a component of quadrivalent meningococcal conjugate vaccines that protect against invasive meningococcal disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meningococcal group y polysaccharide diphtheria toxoid conjugate.